Synthesis, biological evaluation, and docking studies of new 2-furylbenzimidazoles as anti-angiogenic agents: part II.
- Additional Document Info
- View All
The 2-(5-methyl-2-furyl)-1H-benzimidazole moiety has shown promising activity against vascular endothelial growth factor (VEGF)-induced angiogenesis. In part I of this study, we have synthesized new analogs and tested their anti-angiogenic potentials. Here, we continue our previous study with different new analogs. Some compounds show promising cytotoxic activity against the human breast cancer cell line MCF-7, with IC50 in the range of 7.80-13.90g/mL, and exhibited remarkable in vitro inhibition against VEGF in the MCF-7 cancer cell line, with 95-98% of inhibition in comparison to tamoxifen as reference (IC50: 8.00g/mL, % of inhibition=98%). Additionally, a molecular docking study was carried out to gain insight into plausible binding modes and to understand the structure-activity relationships of the synthesized compounds.
author list (cited authors)
Temirak, A., Shaker, Y. M., Ragab, F., Ali, M. M., Soliman, S. M., Mortier, J., ... El Diwani, H. I.
complete list of authors
Temirak, Ahmed||Shaker, Yasser M||Ragab, Fatma AF||Ali, Mamdouh M||Soliman, Salwa M||Mortier, Jeremie||Wolber, Gerhard||Ali, Hamed I||El Diwani, Hoda I